BIOMAT Database Logo BIOMAT Database Logo

Treatment complexities in psychosis associated with cabergoline treatment in patients having pituitary prolactinomas. 2018

Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India. Electronic address: pg_aiims@yahoo.co.in.

UI MeSH Term Description Entries
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D011605 Psychoses, Substance-Induced Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance. Psychoses, Drug,Psychoses, Toxic,Substance-Induced Psychoses,Toxic Psychoses,Drug Psychoses,Psychoses, Substance Induced,Substance Induced Psychoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077465 Cabergoline An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE. 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea,1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate,Cabaser,Cabaseril,Cabergoline Diphosphate,Dostinex,FCE 21336,FCE-21336,Galastop
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid
D015175 Prolactinoma A pituitary adenoma which secretes PROLACTIN, leading to HYPERPROLACTINEMIA. Clinical manifestations include AMENORRHEA; GALACTORRHEA; IMPOTENCE; HEADACHE; visual disturbances; and CEREBROSPINAL FLUID RHINORRHEA. Adenoma, Prolactin-Secreting, Pituitary,PRL-Secreting Pituitary Adenoma,Pituitary Adenoma, Prolactin-Secreting,Lactotroph Adenoma,Macroprolactinoma,Microprolactinoma,Prolactin-Producing Pituitary Adenoma,Prolactin-Secreting Pituitary Adenoma,Prolactinoma, Familial,Adenoma, Lactotroph,Adenomas, Lactotroph,Lactotroph Adenomas,Macroprolactinomas,Microprolactinomas,PRL Secreting Pituitary Adenoma,PRL-Secreting Pituitary Adenomas,Pituitary Adenoma, PRL-Secreting,Pituitary Adenoma, Prolactin Secreting,Pituitary Adenoma, Prolactin-Producing,Pituitary Adenomas, PRL-Secreting,Pituitary Adenomas, Prolactin-Producing,Pituitary Adenomas, Prolactin-Secreting,Prolactin Producing Pituitary Adenoma,Prolactin Secreting Pituitary Adenoma,Prolactin-Producing Pituitary Adenomas,Prolactin-Secreting Pituitary Adenomas,Prolactinomas
D018491 Dopamine Agonists Drugs that bind to and activate dopamine receptors. Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine
D018682 GABA Agents Substances used for their pharmacological actions on GABAergic systems. GABAergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function. gamma-Aminobutyric Acid Agents,GABA Effect,GABA Effects,GABAergic Agent,GABAergic Agents,GABAergic Effect,GABAergic Effects,Acid Agents, gamma-Aminobutyric,Agent, GABAergic,Agents, GABA,Agents, GABAergic,Agents, gamma-Aminobutyric Acid,Effect, GABA,Effect, GABAergic,Effects, GABA,Effects, GABAergic,gamma Aminobutyric Acid Agents

Related Publications

Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
[Postpartum psychosis associated with cabergoline].
January 2013, Medicina clinica,
Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Neuropsychiatric Effects in Patients With Invasive Prolactinomas Treated With Cabergoline.
June 2023, Cureus,
Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Giant prolactinomas in men: efficacy of cabergoline treatment.
May 2003, Clinical endocrinology,
Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Prolactinomas, cabergoline, and pregnancy.
September 2014, Endocrine,
Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.
January 2009, Pituitary,
Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Cabergoline resistance in pediatric prolactinomas.
May 2009, Journal of pediatric hematology/oncology,
Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Pituitary apoplexy associated with cabergoline therapy.
December 2013, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
December 2008, The Journal of clinical endocrinology and metabolism,
Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
September 2013, European journal of endocrinology,
Prashant Gupta, and Tashi Tundup, and Jawahar Singh, and Koushik Sinha Deb, and Rohit Verma, and Nand Kumar
Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas.
January 2015, Neuroendocrinology,
Copied contents to your clipboard!